CSL Behring

Tweet this page
<
2015
2016
2017
2018
2019
2020
>
No longer registered as of 31 Oct 2020 - Registration as it was on 30 Apr 2020
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 030031840349-92

Overview

Lobbying Costs

75,000€

Financial year: Jul 2018 - Jun 2019

Lobbyists (Full time equivalent)

1.25 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    CSL Behring

    EU Transparency Register

    322536115782-29 First registered on 02 Feb 2015

    Goals / Remit

    The CSL Behring story spans decades of innovation, collaboration, patient focus, and an ongoing drive for excellence. CSL Behring is a global leader in the therapeutic protein industry. Committed to saving and improving the lives of people with rare and serious medical disorders, we research, develop, manufacture and market plasma-derived and recombinant biotherapies.

    Our biotherapies replace components missing in the blood of patients and are used around the world to treat coagulation disorders such as hemophilia and von Willebrand disease (VWD), primary immune deficiencies, hereditary angioedema and inherited respiratory disease, as well as neurological disorders in certain markets. We also manufacture products used in cardiac surgery, organ transplantation, and burn treatment, and to treat acquired bleeding, reverse the effects of warfarin, and prevent hemolytic disease of the newborn. Patients come first in all we do.

    Our products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. CSL Behring is part of the CSL Group which employs more than 20,000 people and does business in 60 countries. CSL Behring is a subsidiary of CSL Limited.

    Main EU files targeted

    CSL Behring participates in policy discussions with the EU institutions and European stakeholders that are pertinent to biopharmaceutical sector. Our foremost priority is to improve access to care for patients with rare and serious diseases. We are particularly interested in the legislative developments in the areas of pharmaceuticals, healthcare, innovation and research, internal market, trade, and business competitiveness.

    Address

    Head Office
    1st Ave, 1020
    King of Prussia PA 19406
    UNITED STATES
    EU Office
    Bedrijvenlaan 11
    Mechelen
    BELGIUM
  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%2
    25%1

    Lobbyists (Full time equivalent)

    1.25

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 19 May 2024

    Name Start date End Date
    Mr Ruediger Gatermann 19 Dec 2019 14 Nov 2020
    Ms Joelle Khraiche 24 Sep 2019 01 Oct 2020
    Mr Ruediger Gatermann 15 Jan 2019 19 Dec 2019
    Ms Joelle Khraiche 14 Jun 2018 14 Jun 2019
    Mr Ruediger Gatermann 20 Jan 2018 15 Jan 2019
    Ms Joelle Khraiche 20 Jul 2017 14 Jun 2018
    Mr Dennis Jackman 21 Feb 2017 15 Feb 2018
    Mr Ruediger Gatermann 21 Feb 2017 20 Jan 2018
    Ms Lena Bera 23 Feb 2016 20 Feb 2017
    Mr Dennis Jackman 13 Feb 2016 12 Feb 2017
    Mr Ruediger Gatermann 13 Feb 2016 12 Feb 2017
    Mr Dennis Jackman 18 Feb 2015 13 Feb 2016
    Ms Lena Bera 20 Feb 2015 18 Feb 2016
    Mr Ruediger Gatermann 20 Feb 2015 13 Feb 2016

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Plasma Protein Therapeutic Association (PPTA)
    The European Association of Bio-Industries (EuropaBio)
    European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jul 2018 - Jun 2019

    Lobbying costs for closed financial year

    75,000€

    Other financial info

    This number takes into account percentage of time / costs related to direct employees' activities in this regard. Trade associations’ membership fees are not included to avoid double counting.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard